Update in the management of prostate cancer.
Prostate cancer remains one of the commonest malignancies in our community, and it appears that its incidence is rising because of the increasing proportion of the aged population. Improved technology, including the development of new tumour markers and tumour imaging techniques, and a gradually increasing community awareness of this disease, may allow earlier diagnosis. In turn, as the proportion of patients presenting with early stage disease increases, improved approaches to the treatment of localized cancer may thus yield increased community cure rates. The mainstay of treatment of advanced disease remains hormonal manipulation. The introduction of the LHRH agonists has provided an alternative to surgical castration, but has not resulted in an improved response rate or survival from first-line therapy. We believe that these agents do not offer a major benefit, when compared with the simple procedure of orchidectomy, notwithstanding the psychological sequelae of castration. With a median survival of less than five years after hormonal manipulation, many patients still require salvage treatment after relapse. New hormonal therapies yield objective and subjective response rates of approximately 15% and 30%, respectively, but the median survival from the time of hormonal failure remains less than one year. Cytotoxic chemotherapy has not provided a panacea, but has shown definite evidence of antitumour activity in this disease. The use of relatively non-toxic single cytotoxic drugs can provide effective palliation of symptoms in up to 40% of patients and may even prolong survival in some patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Royal Prince Alfred Hospital, Camperdown, NSW.
D
D
Raghavan
J
J
Rogers
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D003131:Combined Modality Therapy; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D015995:Prevalence; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000473:pathology / Q000628:therapy*
D014408:Biomarkers, Tumor; D007987:Gonadotropin-Releasing Hormone